European Commission Grants Conditional Marketing Approval of Lynozyfi (linvoseltamab) for Relapsed/Refractory Multiple Myeloma (https://www.myeloma.org/news-events/multiple-myeloma-news/european-commission-approves-lynozyfic-linvoseltamab-rrmm)